# Core Laboratories Inc. (CLB)

> Source: Nexqual · https://nexqual.com/CLB · data as of 2026-10-28 20:03 UTC · cite as "Nexqual, Core Laboratories Inc. (CLB), nexqual.com/CLB" · informational, not investment advice.

**Price:** USD 10.49 (+1.55% on the day) · last close of Oct 28, 2026; US market after hours, not a live price. Prev close 10.33 · day 10.26–10.61 · 52w 9.13–20.36 · market cap $481M · NYQ

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $519M, net income $24.4M (4.7% margin), free cash flow $15.1M (SEC filings).
- Valuation: P/E 19.8x (avg 24.9x at the last 3 fiscal year-ends), EV/EBITDA 9.2x, net debt $93.6M.
- 1 of 80 tracked superinvestors hold CLB (13F, Q2 2026): 0 new, 1 added, 0 reduced, 0 unchanged.
- Insider open-market purchases, last ~7 months: 1 Form 4 filing, $54K; 0 by opportunistic insiders, 0 by routine insiders.
- Analysts: Hold (mean 2.67 on a 1–5 scale) (3 analysts), mean target USD 15 (range 11–21).
- Total return with dividends: 1Y -34.7% vs S&P 500 +13.6%.
- Next earnings: 2026-10-28, EPS estimate USD 0.16, revenue estimate $132M.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $470M | $490M | $510M | $524M | $527M | $519M |
| Gross profit | — | $96.1M | $110M | $103M | $109M | — |
| Operating income | $45.3M | $41.5M | $54.6M | $58.6M | $56.5M | $47.8M |
| Net income | $19.7M | $19.5M | $36.7M | $31.4M | $29.7M | $24.4M |
| EPS (diluted) | $0.42 | $0.42 | $0.77 | $0.66 | $0.63 | — |
| Free cash flow | $23.0M | $14.7M | $14.2M | $44.5M | $25.8M | $15.1M |
| Gross margin | — | 19.6% | 21.5% | 19.7% | 20.7% | — |
| Operating margin | 9.6% | 8.5% | 10.7% | 11.2% | 10.7% | 9.2% |
| Net margin | 4.2% | 4.0% | 7.2% | 6.0% | 5.6% | 4.7% |
| Revenue growth | — | +4.1% | +4.1% | +2.8% | +0.5% | — |
| Cash + short-term investments | $17.7M | $15.4M | $15.1M | $19.2M | $22.7M | — |
| Total debt | — | $175M | $166M | $128M | $113M | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/E 19.8x · P/S 0.9x · EV/EBITDA 9.2x · EV/Sales 1.1x · P/FCF 31.8x · P/B 1.8x · FCF yield 3.14% · Earnings yield 5.06% · Dividend yield (paid, TTM) 0.38% · Buyback yield (TTM) 2.98% · Net debt $93.6M · EV $575M
P/E at fiscal year-ends: Dec 2025 25.4x, Dec 2024 26.3x, Dec 2023 22.9x.

## Superinvestors (SEC 13F-HR, Q2 2026)
1 of 80 tracked investors hold CLB. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| John Rogers | Ariel Investments | 1.63% | $164M | Added +6.9% |

## Insider purchases (SEC Form 4, open-market, last ~7 months)
1 purchase, $54K. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-07-31 | Bruno Lawrence | Chairman and CEO | 5,000 | $54K | 10.78 | Too little history (no open-market trades in 2023–2025) |
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Analysts
Consensus Hold (mean 2.67 on a 1–5 scale), 3 analysts; mean target USD 15 (low 11, high 21).

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-29) |
|---|---|
| Total return | -34.7% |
| S&P 500 (SPY) | +13.6% |
| Per year | -34.8% |
| Volatility (annualized) | 46.4% |
| Max drawdown | -52.1% (Jan 2026→Oct 2026) |

## More
Full page: https://nexqual.com/CLB · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $0.16 | $0.15 | +3.2% | $132.1M | 3 |
| Next quarter (ends 2026-12-31) | $0.17 | $0.21 | -19.0% | $133.3M | 3 |
| Current fiscal year (ends 2026-12-31) | $0.51 | $0.54 | -6.2% | $511.9M | 3 |
| Next fiscal year (ends 2027-12-31) | $0.69 | $0.85 | -19.3% | $524.8M | 3 |

## Earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Jun 30, 2026 | $0.11 | $0.09 | Beat +22.2% | — |
| — | Quarter ended Mar 31, 2026 | $0.06 | $0.11 | Miss −45.5% | — |
| — | Quarter ended Dec 31, 2025 | $0.21 | $0.19 | Beat +10.5% | — |
| — | Quarter ended Sep 30, 2025 | $0.22 | $0.19 | Beat +15.8% | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

## Recent SEC filings (last 120 days)
| Filed | Form | What it says | Filing |
|---|---|---|---|
| 2026-10-28 | 8-K | Quarterly results; Regulation FD disclosure | https://www.sec.gov/Archives/edgar/data/1958086/000119312526436200/0001193125-26-436200-index.htm |
| 2026-08-25 | 8-K | Director or executive officer change, or pay arrangement — “On August 19, 2026, Kwaku Temeng verbally notified the Board of Directors of Core Laboratories Inc. (the "Company") of his intention to resign as a director of the Company effective October 1, 2026. Subsequently, on August 25, 2026, Mr. Temeng confirmed his resignation by letter addressed to the Board of Directors. Mr. Temeng serves as Chairman of the Nominating Committee and as a member of the Compensation Committee. As stated in his letter, Mr. Temeng's resignation was due to a disagreement with the Board of…” | https://www.sec.gov/Archives/edgar/data/1958086/000119312526365271/0001193125-26-365271-index.htm |
| 2026-08-14 | Schedule 13G/A | DISCIPLINED GROWTH INVESTORS INC /MN: 6.6% of shares, passive 5%+ holder (amended) | https://www.sec.gov/Archives/edgar/data/1958086/000105044226000023/0001050442-26-000023-index.htm |
| 2026-08-14 | Schedule 13G/A | Ariel Investments, LLC: 30.5% of shares, passive 5%+ holder (amended) | https://www.sec.gov/Archives/edgar/data/1958086/000093675326000045/0000936753-26-000045-index.htm |
| 2026-08-06 | Schedule 13G/A | BlackRock, Inc.: 8.3% of shares, passive 5%+ holder (amended) | https://www.sec.gov/Archives/edgar/data/1958086/000201238326003225/0002012383-26-003225-index.htm |
| 2026-07-30 | 10-Q | Quarterly report · period ended Jun 30, 2026 | https://www.sec.gov/Archives/edgar/data/1958086/000119312526326345/0001193125-26-326345-index.htm |
| 2026-07-29 | 8-K | Quarterly results; Regulation FD disclosure | https://www.sec.gov/Archives/edgar/data/1958086/000119312526324101/0001193125-26-324101-index.htm |
Source: SEC EDGAR. Quotes are the opening words of each item as filed.